Maze Therapeutics, Inc. (MAZE)

NASDAQ: MAZE · Real-Time Price · USD

29.43

+0.50 (1.73%)

Aug 21, 2026, 4:00 PM EDT - Market closed

Maze Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	20	-	167.5	-	-
Revenue Growth	700.00%	-	-	-	-
Gross Profit	20	-	167.5	-	-
Operating Income	-145.61	-142.9	57.59	-98.55	-111.03
Net Income	-133.59	-131.12	3.41	-100.42	-114.94
Earnings Per Share	-2.52	-3.05	1.25	-43.89	-57.18
EPS Growth	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Investments	494.91	341.92	196.81	29.16	99.92
Total Debt	60.42	23.31	26.63	49.62	32.06
Net Cash (Debt)	434.49	318.61	170.18	-20.47	67.86
Net Cash Growth	81.39%	87.22%	-	-	-
Net Cash Per Share	8.19	7.41	62.33	-8.94	33.76

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Cash Flow	-106.54	-111.94	75.95	-86.83	-99.2
Capital Expenditures	-0.3	-0.79	-1.15	-0.44	-1.97
Free Cash Flow	-106.84	-112.73	74.81	-87.27	-101.17
Free Cash Flow Growth	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Gross Margin	100.00%	-	100.00%	-	-
Operating Margin	-728.06%	-	34.38%	-	-
Pretax Margin	-667.95%	-	31.88%	-	-
Profit Margin	-667.95%	-	2.03%	-	-
FCF Margin	-534.20%	-	44.66%	-	-

Valuation

Selected indicators aren't available for this stock.